 Fibrinolysin
"Fibrinolysin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A product of the lysis of plasminogen (profibrinolysin) by PLASMINOGEN activators. It is composed of two polypeptide chains, light (B) and heavy (A), with a molecular weight of 75,000. It is the major proteolytic enzyme involved in blood clot retraction or the lysis of fibrin and quickly inactivated by antiplasmins.
| Descriptor ID |
D005341
|
| MeSH Number(s) |
D08.811.277.656.300.760.330 D08.811.277.656.959.350.330
|
| Concept/Terms |
Fibrinolysin- Fibrinolysin
- Protease F
- Glu-Plasmin
- Glu Plasmin
- Plasmin
|
Below are MeSH descriptors whose meaning is more general than "Fibrinolysin".
Below are MeSH descriptors whose meaning is more specific than "Fibrinolysin".
This graph shows the total number of publications written about "Fibrinolysin" by people in this website by year, and whether "Fibrinolysin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1986 | 1 | 0 | 1 | | 1988 | 0 | 1 | 1 | | 1992 | 0 | 1 | 1 | | 2001 | 2 | 0 | 2 | | 2002 | 1 | 1 | 2 | | 2003 | 0 | 1 | 1 | | 2004 | 0 | 2 | 2 | | 2005 | 0 | 1 | 1 | | 2009 | 0 | 1 | 1 | | 2010 | 2 | 1 | 3 | | 2013 | 2 | 0 | 2 | | 2017 | 0 | 2 | 2 | | 2019 | 0 | 1 | 1 | | 2020 | 0 | 1 | 1 | | 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Fibrinolysin" by people in Profiles.
-
Eton D, Zhou G, He TC, Bartholomew A, Patil R. Filgrastim, fibrinolysis, and neovascularization. J Tissue Eng Regen Med. 2022 05; 16(5):496-510.
-
Dixon AL, McCully BH, Rick EA, Dewey E, Farrell DH, Morrison LJ, McMullan J, Robinson BRH, Callum J, Tibbs B, Dries DJ, Jui J, Gandhi RR, Garrett JS, Weisfeldt ML, Wade CE, Aufderheide TP, Frascone RJ, Tallon JM, Kannas D, Williams C, Rowell SE, Schreiber MA. Tranexamic acid administration in the field does not affect admission thromboelastography after traumatic brain injury. J Trauma Acute Care Surg. 2020 11; 89(5):900-907.
-
Singh SR, Hariprasad SM, Narayanan R. Current Management of Macular Hole. Ophthalmic Surg Lasers Imaging Retina. 2019 02 01; 50(2):61-68.
-
Ishihara J, Fukunaga K, Ishihara A, Larsson HM, Potin L, Hosseinchi P, Galliverti G, Swartz MA, Hubbell JA. Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events. Sci Transl Med. 2017 Nov 08; 9(415).
-
Briquez PS, Lorentz KM, Larsson HM, Frey P, Hubbell JA. Human Kunitz-type protease inhibitor engineered for enhanced matrix retention extends longevity of fibrin biomaterials. Biomaterials. 2017 Aug; 135:1-9.
-
Hoffmann DC, Willenborg S, Koch M, Zwolanek D, Müller S, Becker AK, Metzger S, Ehrbar M, Kurschat P, Hellmich M, Hubbell JA, Eming SA. Proteolytic processing regulates placental growth factor activities. J Biol Chem. 2013 Jun 21; 288(25):17976-89.
-
Ober MD, Hariprasad SM. Ocriplasmin: nonsurgical option for VMA and macular hole, but with potential barriers to practical use. Ophthalmic Surg Lasers Imaging Retina. 2013 Mar-Apr; 44(2):113-6; discussion p.113.
-
Patterson J, Hubbell JA. SPARC-derived protease substrates to enhance the plasmin sensitivity of molecularly engineered PEG hydrogels. Biomaterials. 2011 Feb; 32(5):1301-10.
-
Lorentz KM, Kontos S, Frey P, Hubbell JA. Engineered aprotinin for improved stability of fibrin biomaterials. Biomaterials. 2011 Jan; 32(2):430-8.
-
Jo YS, Rizzi SC, Ehrbar M, Weber FE, Hubbell JA, Lutolf MP. Biomimetic PEG hydrogels crosslinked with minimal plasmin-sensitive tri-amino acid peptides. J Biomed Mater Res A. 2010 Jun 01; 93(3):870-7.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|